Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 8/20 | 0.49 |
| ▸ | P2RX2 | Q9UBL9 | 7/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171032 | 0.93 | P2RX3 (0.49) | P2RX3P2RX2NR1I2CTSACYP2C9 | |
| SCHEMBL2171499 | 0.83 | P2RX3 (0.61) | P2RX3P2RX2NR1I2 | |
| SCHEMBL7947489 | 0.82 | P2RX3 (0.50) | P2RX3P2RX2NR1I2CTSACYP2C9 | |
| SCHEMBL2170986 | 0.81 | NR1I2 (0.45) | P2RX3P2RX2NR1I2CTSAGABRA5 | |
| SCHEMBL2171650 | 0.81 | TAS1R3 (0.45) | P2RX3P2RX2NR1I2TAS1R3TAS1R1 | |
| SCHEMBL2171034 | 0.80 | P2RX3 (0.39) | P2RX3P2RX2NR1I2CTSAGABRA5 | |
| SCHEMBL2187309 | 0.79 | P2RX3 (0.56) | P2RX3P2RX2NR1I2CTSACYP2C9 | |
| SCHEMBL2172956 | 0.78 | NR1I2 (0.45) | P2RX3P2RX2NR1I2CTSA | |
| SCHEMBL2171462 | 0.76 | P2RX3 (0.53) | P2RX3P2RX2NR1I2 | |
| SCHEMBL2171457 | 0.76 | P2RX3 (0.53) | P2RX3P2RX2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133122-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133122-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| EP-2346825-A2 | MODULATORS OF P2X3 RECEPTOR ACTIVITY | Evotec AG (DE) | 2011-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | ADORA2B, IL1B, AVPR1B | P2RX3 207/4885P2RX2 240/4885NR1I2 400/4885 |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | IL1B, ADORA2B, AVPR1B | P2RX3 219/4885P2RX2 259/4885NR1I2 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.